Why Monopar Therapeutics Inc.’s (MNPR) Stock Is Down 5.46%
As of Friday, November 13, Monopar Therapeutics Inc.’s MNPR share price has dipped by 5.46%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Rosalio Madrigal
Tudor Pop
Michael Rose
Michael Rose
| Share Statistics | MNPR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $476.3 | $212.8 | 38% |
|
| Shares Out (Mil) | 8.6 | 55.2 | 19% |
|
| Institutional Ownership | 91.9% | 93.3% | 60% |
|
| Float (Mil) | 4.5 | 40.8 | 11% |
|
| Beta | 1.61 | 1.03 | 85% |
|
| Avg Daily Volume (000s) | 153 | 559 | 41% |
|
| Price Change (52-week) |
(12.8%) | 40.3% | 42% |
|
| Growth | MNPR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (16.8%) | (10.5%) | 23% |
|
| EPS (5yr) | 8.4% | 15.4% | 45 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 6.1% | (15.7%) | 68% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 8 | 8 | |
| Current EPS | ($0.873) | ($2.843) | ($2.785) | |
| Month Ago EPS | ($1.135) | ($3.041) | ($1.916) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($1.092) | ($3.006) | ($1.980) | |
| Year/Year Chg | 20.6% | 53.6% | 96.2% | |
| Financials | MNPR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $40 | na |
|
| Net Income (TTM) (Mil) | ($21) | ($44) | 23% |
|
| EPS (TTM) | ($2.412) | ($1.400) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($16) | ($34) | 16% |
|
| Net Cash Flow (TTM) (Mil) | ($75) | $-0 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 12% |
|
| Enterprise Value (Q1) (Mil) | $359 | $142 | 32% |
|
| Valuation | MNPR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.74 | 1.97 | 75% |
|
| P/E | na | 16.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | MNPR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (15.0%) | (47.4%) | 22% |
|
| ROE | (15.3%) | (51.4%) | 25% |
|
| Liabilities to Assets | 2.4% | 29.6% | 1% |
|
| F-Score | 3 | 3 | 18% |
|
Monopar Therapeutics Inc. did not pass any screens on 11/19/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors